Evidentic GmbH specializes in sourcing clinical-grade molecules by providing aliquots extracted from original EU-licensed drugs. This addresses a significant challenge in early drug development and acquiring various batches of drugs that are typically not concurrently available on the market. By facilitating this process, Evidentic streamlines drug development and enables researchers to obtain the necessary molecules for their studies.